Maiwald blog articles
New fee schedule for the Unified Patent Court (UPC) from 1 January 2026
The Administrative Committee of the UPC has decided on a comprehensive reform of court fees, which will come into force on 1 January 2026. The adjustment affects almost all fe...
Continue reading
Why Patent Defense and Military Technologies?
When developing high-tech technologies for use in defense and military applications, you might wonder whether patent protection is necessary. Even though your customer base is...
Continue reading
Turn one into several – what Rule 80 EPC says about using several independent claims to defend one independent claim
The Board of Appeal of the EPO has issued two decisions concerning appeal cases T 0123/22 and T 1191/22, which relate to the interpretation of Rule 80 EPC. The fundamental que...
Continue reading
EPO Board of Appeal 3.3.04 is setting the right standard for acknowledging novelty of non-medical use claims (T 1913/21)
G 2/88 provides legal assessment for novelty of a non-medical use claim. G 2/88 allows acknowledging novelty of a non-medical use claim of an old compound for a particular pur...
Continue reading
EPO revokes Roche’s Patent on combination therapy of bevacizumab and paclitaxel for platinum-resistant ovarian cancer that was supported by results of Phase III AURELIA clinical trial
European Patent EP 2 825 558 concerns a combination therapy of bevacizumab and paclitaxel for platinum-resistant ovarian cancer. The claim was supported by Phase III AURELIA c...
Continue reading
UPDATE: New proceedings before the Enlarged Board of Appeal: “G2/24 – Skin cleanser”
On the issue of the potential continuation of EPO appeal proceedings by an intervener the questions for referral on which we already reported
Continue reading
